Michihisa Moriguchi

4.3k total citations
113 papers, 2.3k citations indexed

About

Michihisa Moriguchi is a scholar working on Hepatology, Epidemiology and Molecular Biology. According to data from OpenAlex, Michihisa Moriguchi has authored 113 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Hepatology, 46 papers in Epidemiology and 22 papers in Molecular Biology. Recurrent topics in Michihisa Moriguchi's work include Liver Disease Diagnosis and Treatment (39 papers), Hepatocellular Carcinoma Treatment and Prognosis (35 papers) and Cancer Mechanisms and Therapy (14 papers). Michihisa Moriguchi is often cited by papers focused on Liver Disease Diagnosis and Treatment (39 papers), Hepatocellular Carcinoma Treatment and Prognosis (35 papers) and Cancer Mechanisms and Therapy (14 papers). Michihisa Moriguchi collaborates with scholars based in Japan, United States and France. Michihisa Moriguchi's co-authors include Yoshito Itoh, Kanji Yamaguchi, Yuya Seko, Atsushi Umemura, Taichiro Nishikawa, Takeshi Okanoue, Kohichiroh Yasui, Tomoki Nakajima, Hiroyoshi Taketani and Tatsuo Katagishi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Michihisa Moriguchi

109 papers receiving 2.3k citations

Peers

Michihisa Moriguchi

EPIDE

HEPAT

EDM

ONCOL

Kosuke Kaji Japan

Tadashi Namisaki Japan

Mitsuteru Kitade Japan

S. Saccomanno Italy

Hironori Mitsuyoshi Japan

Takemi Akahane Japan

Yasuhide Ikenaka Japan

Jaideep Behari United States

Naoto Fujiwara Japan

Akinobu Takaki Japan

Kosuke Kaji Japan

Michihisa Moriguchi

1.1k ×1.1

EPIDE

902 ×1.1

HEPAT

786 ×1.4

428 ×1.0

EDM

272 ×0.7

ONCOL

Citations per year, relative to Michihisa Moriguchi Michihisa Moriguchi (= 1×) peers Kosuke Kaji

Countries citing papers authored by Michihisa Moriguchi

Since Specialization

Citations

This map shows the geographic impact of Michihisa Moriguchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michihisa Moriguchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michihisa Moriguchi more than expected).

Fields of papers citing papers by Michihisa Moriguchi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michihisa Moriguchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michihisa Moriguchi. The network helps show where Michihisa Moriguchi may publish in the future.

Co-authorship network of co-authors of Michihisa Moriguchi

This figure shows the co-authorship network connecting the top 25 collaborators of Michihisa Moriguchi. A scholar is included among the top collaborators of Michihisa Moriguchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michihisa Moriguchi. Michihisa Moriguchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kudo, Masatoshi, Kazuomi Ueshima, Kaoru Tsuchiya, et al.. (2025). Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study. Liver Cancer. 15(1). 104–116. 3 indexed citations

Kodama, Yoshihisa, Michihisa Moriguchi, Yoshitaka Inaba, et al.. (2025). Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. BMC Cancer. 25(1). 434–434. 3 indexed citations

Ueshima, Kazuomi, Kaoru Tsuchiya, Tatsuya Yamashita, et al.. (2025). Atezolizumab Plus Bevacizumab for TACE ‐Unsuitable Intermediate‐Stage HCC Beyond Up‐To‐7 Criteria: Final Analysis of REPLACEMENT. Liver International. 45(12). e70379–e70379.

Moriguchi, Michihisa, Seita Kataoka, & Yoshito Itoh. (2024). Evolution of Systemic Treatment for Hepatocellular Carcinoma: Changing Treatment Strategies and Concepts. Cancers. 16(13). 2387–2387. 2 indexed citations

Seko, Yuya, Kanji Yamaguchi, Toshihide Shima, et al.. (2024). Prognostic performance of a two‐step method using the Fibro‐Scope system for metabolic dysfunction‐associated steatotic liver disease. Hepatology Research. 55(2). 211–218. 1 indexed citations

Yamaguchi, Kanji, Yusuke Takahashi, Hiroshi Ishiba, et al.. (2024). Hepatocyte-specific GDF15 overexpression improves high-fat diet-induced obesity and hepatic steatosis in mice via hepatic FGF21 induction. Scientific Reports. 14(1). 23993–23993. 7 indexed citations

Doi, Toshifumi, Takeshi Ishikawa, Junichirô Itani, et al.. (2024). Real‐world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications. Cancer Science. 115(11). 3729–3739. 2 indexed citations

Okanoue, Takeshi, Kanji Yamaguchi, Toshihide Shima, et al.. (2023). Artificial intelligence/neural network system that accurately diagnoses hepatocellular carcinoma in nonalcoholic steatohepatitis. Hepatology Research. 53(12). 1213–1223. 3 indexed citations

Yamaguchi, Kanji, Yuya Seko, Takamitsu Sakai, et al.. (2023). Comparison of portal vein hemodynamics with ultrasound-based elastography for the prediction of liver fibrosis in patients with chronic liver disease. Scientific Reports. 13(1). 3425–3425. 3 indexed citations

10.

Umemura, Atsushi, Seita Kataoka, Yuya Seko, et al.. (2022). Potential Therapeutic Targets and Promising Agents for Combating NAFLD. Biomedicines. 10(4). 901–901. 10 indexed citations

11.

Kataoka, Seita, Michihisa Moriguchi, Aya Takahashi, et al.. (2022). Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case. Clinical Journal of Gastroenterology. 15(2). 467–474. 9 indexed citations

12.

Yamaguchi, Kanji, Yuya Seko, Hiroshi Ishiba, et al.. (2021). Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice. Laboratory Investigation. 102(3). 281–289. 42 indexed citations

13.

Umemura, Atsushi, S Umemura, Seita Kataoka, et al.. (2021). Honokiol Prevents Non-Alcoholic Steatohepatitis-Induced Liver Cancer via EGFR Degradation through the Glucocorticoid Receptor—MIG6 Axis. Cancers. 13(7). 1515–1515. 17 indexed citations

14.

Seko, Yuya, Kanji Yamaguchi, Nozomi Tochiki, et al.. (2021). The Effect of Genetic Polymorphism in Response to Body Weight Reduction in Japanese Patients with Nonalcoholic Fatty Liver Disease. Genes. 12(5). 628–628. 11 indexed citations

15.

Umemura, Atsushi, Seita Kataoka, Aya Takahashi, et al.. (2021). Enhanced Antitumor Effect in Liver Cancer by Amino Acid Depletion-Induced Oxidative Stress. Frontiers in Oncology. 11. 758549–758549. 9 indexed citations

16.

Sangro, Bruno, Kazushi Numata, Yi‐Hsiang Huang, et al.. (2021). P-61 Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073. Annals of Oncology. 32. S117–S117. 11 indexed citations

17.

Aramaki, Takeshi, et al.. (2019). A randomized, controlled trial of the efficacy of percutaneous transesophageal gastro-tubing (PTEG) as palliative care for patients with malignant bowel obstruction: the JIVROSG0805 trial. Supportive Care in Cancer. 28(6). 2563–2569. 16 indexed citations

18.

Taketani, Hiroyoshi, Taichiro Nishikawa, Hisakazu Nakajima, et al.. (2019). <p>Aging-associated impairment in metabolic compensation by subcutaneous adipose tissue promotes diet-induced fatty liver disease in mice</p>. Diabetes Metabolic Syndrome and Obesity. Volume 12. 1473–1492. 5 indexed citations

19.

Gen, Yasuyuki, Kohichiroh Yasui, Tomoko Kitaichi, et al.. (2017). ASPP2 suppresses invasion and TGF-β1-induced epithelial–mesenchymal transition by inhibiting Smad7 degradation mediated by E3 ubiquitin ligase ITCH in gastric cancer. Cancer Letters. 398. 52–61. 27 indexed citations

20.

Aramaki, Takeshi, et al.. (2012). Content-based image-retrieval system in chest computed tomography for a solitary pulmonary nodule: method and preliminary experiments. International Journal of Computer Assisted Radiology and Surgery. 7(2). 331–338. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact